KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Work In Process (2016 - 2025)

Pacific Biosciences Of California (PACB) has 15 years of Work In Process data on record, last reported at $27.1 million in Q4 2025.

  • For Q4 2025, Work In Process rose 22.01% year-over-year to $27.1 million; the TTM value through Dec 2025 reached $27.1 million, up 22.01%, while the annual FY2025 figure was $27.1 million, 22.01% up from the prior year.
  • Work In Process reached $27.1 million in Q4 2025 per PACB's latest filing, up from $25.2 million in the prior quarter.
  • Across five years, Work In Process topped out at $27.9 million in Q3 2023 and bottomed at $6.9 million in Q1 2021.
  • Average Work In Process over 5 years is $18.8 million, with a median of $21.7 million recorded in 2023.
  • Peak YoY movement for Work In Process: surged 135.87% in 2023, then plummeted 34.4% in 2024.
  • A 5-year view of Work In Process shows it stood at $8.6 million in 2021, then surged by 63.3% to $14.1 million in 2022, then surged by 96.65% to $27.7 million in 2023, then decreased by 19.82% to $22.2 million in 2024, then rose by 22.01% to $27.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Work In Process were $27.1 million in Q4 2025, $25.2 million in Q3 2025, and $26.9 million in Q2 2025.